Last reviewed · How we verify
Cox2 inhibitor (Celecoxib)
Cox2 inhibitor (Celecoxib) is a COX-2 selective inhibitor (coxib) Small molecule drug developed by Seoul National University Hospital. It is currently FDA-approved for Rheumatoid arthritis, Osteoarthritis, Acute pain. Also known as: Celebrex.
Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins that mediate inflammation and pain.
Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins that mediate inflammation and pain. Used for Rheumatoid arthritis, Osteoarthritis, Acute pain.
At a glance
| Generic name | Cox2 inhibitor (Celecoxib) |
|---|---|
| Also known as | Celebrex |
| Sponsor | Seoul National University Hospital |
| Drug class | COX-2 selective inhibitor (coxib) |
| Target | COX-2 (Cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | FDA-approved |
Mechanism of action
COX-2 is an inducible enzyme responsible for generating pro-inflammatory prostaglandins at sites of inflammation. By selectively blocking COX-2 while sparing COX-1, celecoxib reduces inflammation and pain with potentially fewer gastrointestinal side effects than non-selective NSAIDs. This selectivity makes it useful for chronic inflammatory conditions while theoretically preserving the protective functions of COX-1-derived prostaglandins in the stomach and kidneys.
Approved indications
- Rheumatoid arthritis
- Osteoarthritis
- Acute pain
- Ankylosing spondylitis
- Familial adenomatous polyposis (FAP)
Common side effects
- Hypertension
- Dyspepsia
- Abdominal pain
- Diarrhea
- Headache
- Cardiovascular events (myocardial infarction, stroke)
Key clinical trials
- The Seven Trial: Exploiting the Unfolded Protein Response (PHASE1)
- Celecoxib in Parkinson Disease as Adjuvant Therapy (PHASE1, PHASE2)
- Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions (PHASE1)
- Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer (PHASE2)
- Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) (PHASE2)
- Effects and Mechanisms of Celecoxib on Intracerebral Hemorrhage (PHASE2)
- Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression (PHASE4)
- Preemptive Analgesia With Celecoxib for Acute Dental Pain Management (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cox2 inhibitor (Celecoxib) CI brief — competitive landscape report
- Cox2 inhibitor (Celecoxib) updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI
Frequently asked questions about Cox2 inhibitor (Celecoxib)
What is Cox2 inhibitor (Celecoxib)?
How does Cox2 inhibitor (Celecoxib) work?
What is Cox2 inhibitor (Celecoxib) used for?
Who makes Cox2 inhibitor (Celecoxib)?
Is Cox2 inhibitor (Celecoxib) also known as anything else?
What drug class is Cox2 inhibitor (Celecoxib) in?
What development phase is Cox2 inhibitor (Celecoxib) in?
What are the side effects of Cox2 inhibitor (Celecoxib)?
What does Cox2 inhibitor (Celecoxib) target?
Related
- Drug class: All COX-2 selective inhibitor (coxib) drugs
- Target: All drugs targeting COX-2 (Cyclooxygenase-2)
- Manufacturer: Seoul National University Hospital — full pipeline
- Therapeutic area: All drugs in Rheumatology / Pain Management
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Osteoarthritis
- Indication: Drugs for Acute pain
- Also known as: Celebrex
- Compare: Cox2 inhibitor (Celecoxib) vs similar drugs
- Pricing: Cox2 inhibitor (Celecoxib) cost, discount & access